Pinnacle Associates’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-14,000
| Closed | -$249K | – | 734 |
|
|
2018
Q3 | $249K | Sell |
14,000
-695
| -5% | -$11.9K | 0.01% | 639 |
|
|
2018
Q2 | $203K | Sell |
14,695
-200
| -1% | -$2.37K | ﹤0.01% | 669 |
|
|
2018
Q1 | $135K | Sell |
14,895
-1,500
| -9% | -$8.28K | ﹤0.01% | 662 |
|
|
2017
Q4 | $70K | Sell |
16,395
-16,425
| -50% | -$78.3K | ﹤0.01% | 669 |
|
|
2017
Q3 | $46K | Sell |
32,820
-748,671
| -96% | -$1.04M | ﹤0.01% | 663 |
|
|
2017
Q2 | $1.17M | Sell |
781,491
-25,025
| -3% | -$53.7K | 0.02% | 373 |
|
|
2017
Q1 | $2.07M | Sell |
806,516
-15,027
| -2% | -$34.8K | 0.04% | 312 |
|
|
2016
Q4 | $2.1M | Sell |
821,543
-50,754
| -6% | -$146K | 0.04% | 298 |
|
|
2016
Q3 | $2.69M | Sell |
872,297
-16,560
| -2% | -$51.6K | 0.05% | 268 |
|
|
2016
Q2 | $2.85M | Sell |
888,857
-9,239
| -1% | -$33.9K | 0.06% | 259 |
|
|
2016
Q1 | $2.78M | Buy |
898,096
+42,310
| +5% | +$138K | 0.06% | 254 |
|
|
2015
Q4 | $3.43M | Sell |
855,786
-97,647
| -10% | -$450K | 0.07% | 227 |
|
|
2015
Q3 | $4.37M | Sell |
953,433
-9,435
| -1% | -$49.4K | 0.1% | 204 |
|
|
2015
Q2 | $5M | Sell |
962,868
-33,900
| -3% | -$203K | 0.09% | 199 |
|
|
2015
Q1 | $6.24M | Buy |
996,768
+6,890
| +0.7% | +$39.8K | 0.12% | 175 |
|
|
2014
Q4 | $6.23M | Buy |
989,878
+33,035
| +3% | +$201K | 0.12% | 169 |
|
|
2014
Q3 | $5.82M | Sell |
956,843
-30,380
| -3% | -$207K | 0.12% | 171 |
|
|
2014
Q2 | $6.51M | Sell |
987,223
-48,510
| -5% | -$546K | 0.13% | 160 |
|
|
2014
Q1 | $24.7M | Sell |
1,035,733
-23,770
| -2% | -$345K | 0.48% | 55 |
|
|
2013
Q4 | $11.3M | Sell |
1,059,503
-30,990
| -3% | -$342K | 0.22% | 107 |
|
|
2013
Q3 | $14.5M | Buy |
1,090,493
+621,813
| +133% | +$9.83M | 0.3% | 88 |
|
|
2013
Q2 | $6.15M | Buy |
+468,680
| New | +$6.32M | 0.14% | 154 |
|
Other funds holding ECYT
Pinnacle Associates's ECYT Position: Q4 2018 in Review
Pinnacle Associates sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 14,000 shares — an estimated $249K sold.
Pinnacle Associates first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $24.7M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Pinnacle Associates reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Pinnacle Associates sold 14,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $249K.
- Pinnacle Associates first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- Pinnacle Associates's Endocyte, Inc. Common Stock position peaked at $24.7M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Pinnacle Associates's 13F filing for Q4 2018, filed 5 Feb 2019.